This phase II study evaluated the efficacy and safety of buparlisib plus tamoxifen in pretreated patients with advanced HR+/HER2− breast cancer, stratified for PIK3CA mutations and/or loss of PTEN expression in tumor tissue and circulating blood DNA. Here, PTEN is linked to neoplasm.